AR109454A1 - Composición farmaceutica líquida que comprende un antibiótico glicopéptido y sulfobutiléter - Google Patents

Composición farmaceutica líquida que comprende un antibiótico glicopéptido y sulfobutiléter

Info

Publication number
AR109454A1
AR109454A1 ARP170101197A ARP170101197A AR109454A1 AR 109454 A1 AR109454 A1 AR 109454A1 AR P170101197 A ARP170101197 A AR P170101197A AR P170101197 A ARP170101197 A AR P170101197A AR 109454 A1 AR109454 A1 AR 109454A1
Authority
AR
Argentina
Prior art keywords
antibiotic
pharmaceutical composition
sulfobutiletter
glicopeptide
composition liquid
Prior art date
Application number
ARP170101197A
Other languages
English (en)
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of AR109454A1 publication Critical patent/AR109454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica líquida que comprende un antibiótico glicopéptido y sulfobutiléter b ciclodextrina, donde la composición farmacéutica es estable durante al menos aproximadamente cuatro semanas a 25ºC en un recipiente cerrado. Reivindicación 2: La composición farmacéutica de la reivindicación 1, donde el antibiótico glicopéptido es vancomicina, teicoplanina, telavancina, dalbavancina u oritavancina. Reivindicación 23: Un método para estabilizar un antibiótico glicopéptido en una solución farmacéutica líquida, que comprende mezclar sulfobutiléter b ciclodextrina y el antibiótico glicopéptido en una relación de antibiótico glicopéptido a sulfobutiléter b ciclodextrina en la cual la solución farmacéutica es estable durante al menos aproximadamente cuatro semanas a 25 grados Celsius en un recipiente cerrado.
ARP170101197A 2016-05-09 2017-05-08 Composición farmaceutica líquida que comprende un antibiótico glicopéptido y sulfobutiléter AR109454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09

Publications (1)

Publication Number Publication Date
AR109454A1 true AR109454A1 (es) 2018-12-12

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101197A AR109454A1 (es) 2016-05-09 2017-05-08 Composición farmaceutica líquida que comprende un antibiótico glicopéptido y sulfobutiléter

Country Status (20)

Country Link
US (1) US10729708B2 (es)
EP (1) EP3454883A1 (es)
JP (1) JP6946343B2 (es)
KR (1) KR20190005940A (es)
CN (1) CN109069580A (es)
AR (1) AR109454A1 (es)
AU (1) AU2017262943B2 (es)
BR (1) BR112018072948A2 (es)
CA (1) CA3021935A1 (es)
CL (1) CL2018003147A1 (es)
CO (1) CO2018011701A2 (es)
EA (1) EA201892413A1 (es)
IL (1) IL262796A (es)
JO (2) JOP20170111B1 (es)
MX (1) MX2018013584A (es)
SA (1) SA518400392B1 (es)
SG (1) SG11201809908TA (es)
TW (2) TWI769694B (es)
UY (1) UY37233A (es)
WO (1) WO2017194385A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703568WA (en) 2014-11-06 2017-05-30 Xellia Pharmaceuticals Aps Glycopeptide compositions
US20210346288A1 (en) * 2020-05-11 2021-11-11 Cai Gu Huang Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
WO2023211501A1 (en) * 2022-04-26 2023-11-02 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
AU1407197A (en) * 1995-12-01 1997-06-19 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
EP1276759B1 (en) * 2000-05-02 2008-07-30 Theravance, Inc. Reductive alkylation process on glycopeptides
BR0110530A (pt) 2000-05-02 2003-04-08 Theravance Inc Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
KR100858945B1 (ko) * 2000-06-21 2008-09-17 큐비스트 파마슈티컬즈 인코포레이티드 항미생물제의 경구 흡수를 개선하기 위한 조성물 및 방법
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
CA2543443A1 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
CN101080221A (zh) 2005-02-14 2007-11-28 维纳斯药业有限公司 抗药性细菌感染疾病的肠胃外综合治疗
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
EA017564B1 (ru) 2007-09-12 2013-01-30 Тарганта Терапьютикс Корп. Способ ингибирования клостридиум диффициле введением оритаванцина
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
ES2743039T3 (es) * 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2014194296A1 (en) 2013-05-30 2014-12-04 Scidose, Llc Formulations of vancomycin
SG11201703568WA (en) * 2014-11-06 2017-05-30 Xellia Pharmaceuticals Aps Glycopeptide compositions
EA036750B1 (ru) 2016-01-08 2020-12-16 Гуфик Байосайенсиз Лимитед Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления
RU2018129076A (ru) * 2016-02-18 2020-03-18 Мелинта Терапьютикс, Инк. Составы оритаванцина

Also Published As

Publication number Publication date
EA201892413A1 (ru) 2019-05-31
TWI769694B (zh) 2022-07-01
US10729708B2 (en) 2020-08-04
BR112018072948A2 (pt) 2019-02-19
MX2018013584A (es) 2019-04-01
TW201740955A (zh) 2017-12-01
SG11201809908TA (en) 2018-12-28
KR20190005940A (ko) 2019-01-16
CA3021935A1 (en) 2017-11-16
AU2017262943A1 (en) 2018-11-22
TW202133875A (zh) 2021-09-16
UY37233A (es) 2018-01-02
WO2017194385A1 (en) 2017-11-16
JOP20220039A1 (ar) 2023-01-30
CO2018011701A2 (es) 2019-02-08
CN109069580A (zh) 2018-12-21
JP2019518733A (ja) 2019-07-04
JP6946343B2 (ja) 2021-10-06
TWI772296B (zh) 2022-08-01
SA518400392B1 (ar) 2022-05-09
EP3454883A1 (en) 2019-03-20
IL262796A (en) 2018-12-31
AU2017262943B2 (en) 2020-05-14
US20190175632A1 (en) 2019-06-13
CL2018003147A1 (es) 2018-12-28
JOP20170111B1 (ar) 2022-03-14

Similar Documents

Publication Publication Date Title
AR109454A1 (es) Composición farmaceutica líquida que comprende un antibiótico glicopéptido y sulfobutiléter
EA202090868A1 (ru) Составы
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
CY1120937T1 (el) Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
ECSP18093651A (es) Formulación farmacéutica líquida estable
BR112017018941B8 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
UY36157A (es) Composiciones pesticidas y procedimientos relacionados con las mismas
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BR112017018987A2 (pt) alimentador de partículas
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
CO2017000030A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
AR098168A1 (es) Formulación estable de insulina glulisina
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
AR108769A1 (es) Procedimiento de preparación de un alimento con polvo dispersable en agua que contiene un componente de semilla de legumbre descascarada
CL2017002676A1 (es) Método de monomerizacion de moléculas recombinantes de anticuerpo
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
BR112017014683A2 (pt) inibidor de patógenos melhorado
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
AR097486A1 (es) Plantas de cítricos resistentes a huanglongbing de cítricos (ex enverdecimiento) producido por candidatus liberibacter asiaticus (las) y chancro bacteriano producido por xanthomonas axonopodis pv. citri (xac)
BR112015022484A2 (pt) formulações com oxidação reduzida
MX2019014666A (es) Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo.
MX2019008773A (es) Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure